Name: Pet Cancer Therapeutics Market Size, Competitive Landscape and Market Forecast - 2029
Brand: DataM Intelligence
SKU: DMVH1368
Price: 4350 USD
Availability: InStock

Pet Cancer Therapeutics Market Size Share Growth Opportunities and Forecast 2022

Pet Cancer Therapeutics Market Size, Competitive Landscape and Market Forecast - 2029

<h2>Global Pet Cancer Therapeutics Market Size By Medicine Type (Chemotherapy Drugs, Vaccines, Immunotherapy, and others), By Animal(Dogs, Cats, Horses, and others), By Cancer Type (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, and Squamous Cell Cancer), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

<h2>&nbsp;</h2>

<h2>Market Overview</h2>

<blockquote>
The &quot;Pet Cancer Therapeutics Market&quot;&nbsp;is expected to grow at a <a href="https://www.datamintelligence.com/download-sample/pet-cancer-therapeutics-market">CAGR of 9.1%</a> during the forecasting period (2022-2029).
</blockquote>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics:</h3>

<a href="https://www.datamintelligence.com/research-report/lactated-ringers-injection-market">Lactated Ringers Injection Market</a>

<a href="https://www.datamintelligence.com/research-report/stem-cell-therapy-for-diabetes-and-related-conditions-market">Stem Cell Therapy for Diabetes and Related Conditions Market</a>

<a href="https://www.datamintelligence.com/research-report/companion-animal-ear-infection-treatment-market">Companion Animal Ear Infection Treatment Market</a>

<h2>&nbsp;</h2>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px"><big>Table of Contents</big></h2>

1. Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Medication Type

3.2. Market Snippet by Animal

3.3. Market Snippet by Cancer Type

3.4. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. High Prevalence of Cancer in Pets

4.1.1.2. Launch of novel drugs

4.1.2. Restraints

4.1.2.1. High Cost of pet cancer drugs

4.1.3. Opportunity

4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter&#39;s Five Forces Analysis

5.2. Regulatory Analysis

5.3. Patent Analysis

6. Epidemiology Analysis

7. Pipeline Analysis

8. By Medication Type

8.1.1. &nbsp;Introduction

8.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

8.1.3. Market Attractiveness Index, By Medication Type

8.2. Chemotherapy Drugs

8.2.1. Introduction

8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

8.3. Targeted Drugs

8.4. Immunotherapy

8.5. Vaccines

8.6. Others

9. By Animal

9.1.1. &nbsp;Introduction

9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

9.1.3. Market Attractiveness Index, By Animal

9.2. Dogs

9.2.1. Introduction

9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

9.3. &nbsp;Cats

9.4. Horses

9.5. Others

10. By Cancer Type

10.1.1. &nbsp;Introduction

10.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

10.1.3. Market Attractiveness Index, By Cancer Type

10.2. Lymphoma

10.2.1. Introduction

10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

10.3. &nbsp;Melanoma

10.4. Squamous Cell Cancers

10.5. Others

11. By Region

11.1. Introduction

11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.2.6.1. The U.S.

11.2.6.2. Canada

11.2.6.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.3.6.1. Germany

11.3.6.2. The U.K.

11.3.6.3. France

11.3.6.4. Italy

11.3.6.5. Spain

11.3.6.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.6.1. Brazil

11.4.6.2. Argentina

11.4.6.3. Rest of South America

11.5. Asia Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.6.1. China

11.5.6.2. India

11.5.6.3. Japan

11.5.6.4. Australia

11.5.6.5. Rest of Asia Pacific

11.6. Middle East &amp; Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication Type

11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal

12. Competitive Landscape

12.1. Competitive Scenario

12.2. Competitor Pet Cancer Therapeutics Strategy Analysis

12.3. Comparative Product Portfolio Analysis

12.4. Market Positioning/Share Analysis

12.5. Mergers and Acquisitions Analysis

13. - Company Profiles

13.1. Zoetis

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Key Highlights

13.1.4. Financial Overview

13.2. Merial (Boehringer Ingelheim GmbH)

13.3. Aratana Therapeutics

13.4. &nbsp;Morphogenesis Inc

13.5. &nbsp;Vetivax

13.6. VetDC

13.7. &nbsp;Regeneus

13.8. &nbsp;Karyopharms Verdinexor

13.9. &nbsp;AdvaVet Inc. (Oasmia Pharmaceuticals AB)

13.10. CanFel Therapeutics

14. DataM Intelligence

14.1. Appendix

14.2. About Us and Services

14.3. Contact Us

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px"><big>List of Tables &amp; Figures</big></h2>

<h3>List of Tables&nbsp;</h3>

TABLE 01.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, 2021, 2025 &amp; 2029 , BY MEDICATION TYPE, ($MILLION)

TABLE 02.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029 , BY CANCER TYPE, ($MILLION)

TABLE 03.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029 , BY ANIMAL, ($MILLION)

TABLE 04.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029 , BY REGION, ($MILLION)

TABLE 05.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY MEDICATION TYPE ($MILLION)

TABLE 06.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 07.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY CANCER TYPE ($MILLION)

TABLE 08.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY APPLICATION, 2018&ndash;2029 ($MILLION)

TABLE 09.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY ANIMAL ($MILLION)

TABLE 10.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 11.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY REGION ($MILLION)

TABLE 12.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY REGION, 2018&ndash;2029 ($MILLION)

TABLE 13.&nbsp; &nbsp; NORTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 14.&nbsp; &nbsp; NORTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

TABLE 15.&nbsp; &nbsp; NORTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 16.&nbsp; &nbsp; NORTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 17.&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 18.&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

TABLE 19.&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 20.&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 21.&nbsp; &nbsp; EUROPE PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 22.&nbsp; &nbsp; EUROPE PET CANCER THERAPEUTICS MARKET VALUE, BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

TABLE 23.&nbsp; &nbsp; EUROPE PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 24.&nbsp; &nbsp; EUROPE PET CANCER THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 25.&nbsp; &nbsp; ASIA PACIFIC PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 26.&nbsp; &nbsp; ASIA PACIFIC PET CANCER THERAPEUTICS MARKET VALUE, BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

TABLE 27.&nbsp; &nbsp; ASIA PACIFIC PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 28.&nbsp; &nbsp; ASIA PACIFIC PET CANCER THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 29.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PET CANCER THERAPEUTICS MARKET VALUE, BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

TABLE 30.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PET CANCER THERAPEUTICS MARKET VALUE, BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

TABLE 31.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PET CANCER THERAPEUTICS MARKET VALUE, BY ANIMAL, 2018&ndash;2029 ($MILLION)

TABLE 32.&nbsp; &nbsp; ZOETIS: OVERVIEW

TABLE 33.&nbsp; &nbsp; ZOETIS: PRODUCT PORTFOLIO

TABLE 34.&nbsp; &nbsp; ZOETIS: KEY DEVELOPMENTS

TABLE 35.&nbsp; &nbsp; MERIAL (BOEHRINGER INGELHEIM GMBH): OVERVIEW

TABLE 36.&nbsp; &nbsp; MERIAL (BOEHRINGER INGELHEIM GMBH): PRODUCT PORTFOLIO

TABLE 37.&nbsp; &nbsp; MERIAL (BOEHRINGER INGELHEIM GMBH): KEY DEVELOPMENTS

TABLE 38.&nbsp; &nbsp; ARATANA THERAPEUTICS: OVERVIEW

TABLE 39.&nbsp; &nbsp; ARATANA THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 40.&nbsp; &nbsp; ARATANA THERAPEUTICS: KEY DEVELOPMENTS

TABLE 41.&nbsp; &nbsp; MORPHOGENESIS INC.: OVERVIEW

TABLE 42.&nbsp; &nbsp; MORPHOGENESIS INC.: PRODUCT PORTFOLIO

TABLE 43.&nbsp; &nbsp; MORPHOGENESIS INC.: KEY DEVELOPMENTS

TABLE 44.&nbsp; &nbsp; VETIVAX: OVERVIEW

TABLE 45.&nbsp; &nbsp; VETIVAX: PRODUCT PORTFOLIO

TABLE 46.&nbsp; &nbsp; VETIVAX: KEY DEVELOPMENTS

TABLE 47.&nbsp; &nbsp; VETDC: OVERVIEW

TABLE 48.&nbsp; &nbsp; VETDC: PRODUCT PORTFOLIO

TABLE 49.&nbsp; &nbsp; VETDC: KEY DEVELOPMENTS

TABLE 50.&nbsp; &nbsp; REGENEUS: OVERVIEW

TABLE 51.&nbsp; &nbsp; REGENEUS: PRODUCT PORTFOLIO

TABLE 52.&nbsp; &nbsp; REGENEUS: KEY DEVELOPMENTS

TABLE 53.&nbsp; &nbsp; KARYOPHARMS VERDINEXOR: OVERVIEW

TABLE 54.&nbsp; &nbsp; KARYOPHARMS VERDINEXOR: PRODUCT PORTFOLIO

TABLE 55.&nbsp; &nbsp; KARYOPHARMS VERDINEXOR: KEY DEVELOPMENTS

TABLE 56.&nbsp; &nbsp; ADVAVET INC. (OASMIA PHARMACEUTICALS AB): OVERVIEW

TABLE 57.&nbsp; &nbsp; ADVAVET INC. (OASMIA PHARMACEUTICALS AB): PRODUCT PORTFOLIO

TABLE 58.&nbsp; &nbsp; ADVAVET INC. (OASMIA PHARMACEUTICALS AB): KEY DEVELOPMENTS

TABLE 59.&nbsp; &nbsp; CANFEL THERAPEUTICS: OVERVIEW

TABLE 60.&nbsp; &nbsp; CANFEL THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 61.&nbsp; &nbsp; CANFEL THERAPEUTICS: KEY DEVELOPMENTS

<h3>List of Figures</h3>

FIGURE 01.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY MEDICATION TYPE

FIGURE 02.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY CANCER TYPE

FIGURE 03.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY ANIMAL

FIGURE 04.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY REGION

FIGURE 05.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, 2018 - 2029 AND YEAR ON YEAR GROWTH

FIGURE 06.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY MEDICATION TYPE&nbsp;

FIGURE 07&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY CHEMOTHERAPY DRUGS, 2018&ndash;2029 ($MILLION)

FIGURE 08&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY TARGETED DRUGS, 2018&ndash;2029 ($MILLION)

FIGURE 09&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY IMMUNOTHERAPY, 2018&ndash;2029 ($MILLION)

FIGURE 10&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY VACCINES, 2018&ndash;2029 ($MILLION)

FIGURE 11&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY OTHERS, 2018&ndash;2029 ($MILLION)

FIGURE 12.&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY CANCER TYPE

FIGURE 13&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY MAST CELL CANCER, 2018&ndash;2029 ($MILLION)

FIGURE 14&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY LYMPHOMA, 2018&ndash;2029 ($MILLION)

FIGURE 15&nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY MELANOMA, 2018&ndash;2029 ($MILLION)

FIGURE 16&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY SQUAMOUS CELL CANCER, 2018&ndash;2029 ($MILLION)

FIGURE 17&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY OTHERS, 2018&ndash;2029 ($MILLION)

FIGURE 17&nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY ANIMAL

FIGURE 18&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY CATS, 2018&ndash;2029 ($MILLION)

FIGURE 19&nbsp; &nbsp; &nbsp;GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY DOGS, 2018&ndash;2029 ($MILLION)

FIGURE 20&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY HORSES, 2018&ndash;2029 ($MILLION)

FIGURE 21&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET VALUE, BY OTHERS, 2018&ndash;2029 ($MILLION)

FIGURE 22&nbsp; &nbsp; GLOBAL PET CANCER THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY REGION

FIGURE 23&nbsp; &nbsp; &nbsp;NORTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 24&nbsp; &nbsp; &nbsp;NORTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 25&nbsp; &nbsp; NORTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 26&nbsp; &nbsp; &nbsp;NORTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY ANIMAL, 2018&ndash;2029 ($MILLION)

FIGURE 27&nbsp; &nbsp; &nbsp;NORTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)&nbsp;

FIGURE 28&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 29&nbsp; &nbsp; SOUTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 30&nbsp; &nbsp;SOUTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 31&nbsp; &nbsp; &nbsp;SOUTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY ANIMAL, 2018&ndash;2029 ($MILLION)

FIGURE 32&nbsp; &nbsp; &nbsp;SOUTH AMERICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 33&nbsp; &nbsp; &nbsp;EUROPE PET CANCER THERAPEUTICS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 34 EUROPE PET CANCER THERAPEUTICS MARKET SHARE (%), BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 35&nbsp; &nbsp; &nbsp;EUROPE PET CANCER THERAPEUTICS MARKET SHARE (%), BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 36&nbsp; &nbsp;EUROPE PET CANCER THERAPEUTICS MARKET SHARE (%), BY ANIMAL, 2018&ndash;2029 ($MILLION)

FIGURE 37&nbsp; &nbsp; EUROPE PET CANCER THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 38&nbsp; &nbsp; &nbsp;ASIA PACIFIC PET CANCER THERAPEUTICS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 39&nbsp; &nbsp; ASIA PACIFIC PET CANCER THERAPEUTICS MARKET SHARE (%), BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 40&nbsp; &nbsp;ASIA PACIFIC PET CANCER THERAPEUTICS MARKET SHARE (%), BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 41&nbsp; &nbsp; &nbsp;ASIA PACIFIC PET CANCER THERAPEUTICS MARKET SHARE (%), BY ANIMAL, 2018&ndash;2029 ($MILLION)

FIGURE 42&nbsp; &nbsp; &nbsp;ASIA PACIFIC PET CANCER THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 43&nbsp; &nbsp; MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 44&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY MEDICATION TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 45&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY CANCER TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 46&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET SHARE (%), BY ANIMAL, 2018&ndash;2029 ($MILLION)

FIGURE 47.&nbsp; &nbsp; ZOETIS: FINANCIALS

FIGURE 48.&nbsp; &nbsp; MERIAL (BOEHRINGER INGELHEIM GMBH): FINANCIALS

FIGURE 49.&nbsp; &nbsp; ARATANA THERAPEUTICS: FINANCIALS

FIGURE 50&nbsp; &nbsp;ADVAVET INC. (OASMIA PHARMACEUTICALS AB): FINANCIALS

FIGURE 51.&nbsp; &nbsp; VETIVAX: FINANCIALS

FIGURE 52.&nbsp; &nbsp; VETDC: FINANCIALS

FIGURE 53.&nbsp; &nbsp; &nbsp;REGENEUS: FINANCIALS

FIGURE 54.&nbsp; &nbsp; KARYOPHARMS VERDINEXOR.: FINANCIALS

FIGURE 55.&nbsp; &nbsp; MORPHOGENESIS INC..: FINANCIALS

FIGURE 56.&nbsp; &nbsp; VETDC: FINANCIALS